Frontiers in cancer immunotherapy-a symposium report
| Autor: | Anastasia Maria Zavitsanou, Sofía Bruni, Jennifer Cable, Dana Pe'er, Sumit K. Subudhi, Crystal L. Mackall, Catherine J. Wu, Matthew E. Griffin, Stefani Spranger, Jeffry A. Sosman, Catherine M. Bollard, Mikala Egeblad, Saso Cemerski, James P. Allison, Theresa Proia, Benjamin D. Greenbaum, Renier J. Brentjens, Elaine R. Mardis, Sangeeta Goswami, Garry P. Nolan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.medical_treatment Cancer Vaccines Immunotherapy Adoptive General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Immune system History and Philosophy of Science Cancer immunotherapy Internal medicine Neoplasms medicine Biomarkers Tumor Tumor Microenvironment Humans Immune Checkpoint Inhibitors Tumor microenvironment business.industry General Neuroscience Cancer Immunotherapy medicine.disease Combined Modality Therapy Chimeric antigen receptor 030104 developmental biology 030220 oncology & carcinogenesis Cancer cell Cancer vaccine Neoplasm Recurrence Local business |
| Zdroj: | Annals of the New York Academy of SciencesReferences. 1489(1) |
| ISSN: | 1749-6632 |
| Popis: | Cancer immunotherapy has dramatically changed the approach to cancer treatment. The aim of targeting the immune system to recognize and destroy cancer cells has afforded many patients the prospect of achieving deep, long-term remission and potential cures. However, many challenges remain for achieving the goal of effective immunotherapy for all cancer patients. Checkpoint inhibitors have been able to achieve long-term responses in a minority of patients, yet improving response rates with combination therapies increases the possibility of toxicity. Chimeric antigen receptor T cells have demonstrated high response rates in hematological cancers, although most patients experience relapse. In addition, some cancers are notoriously immunologically "cold" and typically are not effective targets for immunotherapy. Overcoming these obstacles will require new strategies to improve upon the efficacy of current agents, identify biomarkers to select appropriate therapies, and discover new modalities to expand the accessibility of immunotherapy to additional tumor types and patient populations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text